Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketorolac + prednisolone acetate is a fixed-dose combination of two ophthalmic agents used primarily for the treatment and prevention of inflammation and pain following ocular surgery, as well as for other inflammatory eye conditions. Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting prostaglandin synthesis through non-selective inhibition of cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing inflammation and pain[4][8]. Prednisolone acetate is a synthetic glucocorticoid corticosteroid that acts as an anti-inflammatory and immunosuppressive agent by binding to the glucocorticoid receptor, modulating gene expression, suppressing leukocyte infiltration at sites of inflammation, interfering with mediators of inflammatory response, and reducing edema[5]. The combination therapy offers additive or synergistic effects in controlling postoperative ocular inflammation compared to monotherapy[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketorolac + prednisolone acetate.